| answer text |
<p>Whilst no specific assessment has been made of Nolan and Ormondroyd’s systematic
review published in March 2023 or Emma Wilkinson’s article published in October 2022,
the Government recognises both the opportunities and risks raised by direct-to-consumer
genomic tests and is committed to ensuring effective and proportionate regulation.</p><p>In
consideration of the regulation of direct-to-consumer genetic and health testing,
the Medicines and Healthcare products Regulatory Agency is working to develop a robust,
world-leading regulatory regime for such medical devices that prioritises patient
safety.</p>
|
 |
